FDA Launches Unified Adverse Event Monitoring System (AEMS) to Streamline Postmarket Safety Reporting

Details of the Update

The newly introduced AEMS replaces several legacy adverse event reporting systems, including FAERS, VAERS, AERS, MAUDE, HFCS, and CTPAE, bringing all reporting into a centralized platform. This consolidation enables real-time publication of adverse event reports across product categories such as drugs, biologics, vaccines, cosmetics, medical devices, human foods, dietary supplements, animal food, and tobacco products.

The platform introduces enhanced APIs and analytics tools, allowing improved data access and integration for regulatory, quality, and safety functions. These capabilities are intended to support more efficient monitoring, signal detection, and compliance tracking.

Historical data from legacy systems will be migrated into AEMS, with phased decommissioning of previous platforms occurring as migration progresses. By the end of May 2026, AEMS is expected to serve as the primary system for adverse event reporting and visibility across all FDA-regulated sectors.

Stakeholders, including manufacturers, healthcare professionals, and patient safety teams, must adapt their reporting processes to align with the new system requirements during the transition period.

Deadlines

The AEMS platform launched on March 11, 2026, with phased migration and decommissioning of legacy systems expected to be completed by the end of May 2026.

Why It Matters

This update improves transparency and efficiency in postmarket safety surveillance by enabling real-time access to adverse event data across product categories. The centralized system supports digital integration, enhances regulatory oversight, and streamlines data management processes, reducing fragmentation and improving consistency in safety reporting.

Who This Affects

This update is relevant for Regulatory Affairs, Quality Assurance, Patient Safety, and Pharmacovigilance teams across organizations marketing FDA-regulated products, including pharmaceuticals, biologics, medical devices, food products, and tobacco products.

Next Steps

Organizations should evaluate current adverse event reporting workflows and ensure system compatibility with AEMS requirements. Cross-functional teams should collaborate to update internal protocols, align data integration processes, and prepare for real-time reporting and monitoring as the phased migration progresses.

As global regulators continue to modernize safety monitoring systems, maintaining alignment with evolving reporting infrastructures is critical for compliance and risk management.

RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.

FAQs

What is the FDA Adverse Event Monitoring System (AEMS)?

It is a centralized platform for real-time adverse event reporting and monitoring across all FDA-regulated product categories.

Which systems are being replaced by AEMS?

AEMS replaces FAERS, VAERS, AERS, MAUDE, HFCS, and CTPAE, consolidating them into a single system.

When will the transition to AEMS be completed?

The phased migration and decommissioning of legacy systems are expected to be completed by the end of May 2026.

How can RegASK support organizations adapting to AEMS?

RegASK helps organizations track regulatory system changes, align reporting workflows, and streamline compliance processes, ensuring seamless adaptation to new safety monitoring requirements.